Home Use of Maridebart Cafraglutide for Obesity

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

Recruiting Phase 3 Interventional Study
Obesity Overweight
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
230 (estimated)
Sponsor
Amgen · Industry
Who this trial is looking for

This trial is looking for adults who are overweight or obese and want to try a new treatment. Participants will use an autoinjector to give themselves the medication at home.

Are You a Good Fit for This Trial?
Rules you out Type 1 diabetesType 2 diabetesPancreatitisCancer

You may be able to join if

  • I have a BMI of 30 or higher, or I have a BMI of 27 to 30 with a health condition.
  • I have tried to lose weight through diet and exercise before.
  • I use contraception if I am female.
  • I am willing to follow the trial procedures.

You may not be able to join if

  • I have had a significant weight change of more than 5 kg in the last 90 days.
  • I have had surgery for obesity before or I am planning one.
  • I have a history of cancer in the last 5 years.
  • I have Type 1 or Type 2 diabetes.
  • I have chronic pancreatitis or had acute pancreatitis in the last 180 days.
  • I have a family or personal history of medullary thyroid cancer.
  • I have participated in a Maridebart Cafraglutide trial before.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following: * hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg * dyslipidemia: trea…
Contacts

Amgen Call Center

866-572-6436

medinfo@amgen.com

CONTACT